CytoMed Therapeutics Limited Ordinary Shares
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical tr… Read more
CytoMed Therapeutics Limited Ordinary Shares (GDTC) - Net Assets
Latest net assets as of June 2025: $5.68 Million USD
Based on the latest financial reports, CytoMed Therapeutics Limited Ordinary Shares (GDTC) has net assets worth $5.68 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.57 Million) and total liabilities ($892.51K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.68 Million |
| % of Total Assets | 86.42% |
| Annual Growth Rate | 35.93% |
| 5-Year Change | 1738.28% |
| 10-Year Change | N/A |
| Growth Volatility | 737.93 |
CytoMed Therapeutics Limited Ordinary Shares - Net Assets Trend (2019–2024)
This chart illustrates how CytoMed Therapeutics Limited Ordinary Shares's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CytoMed Therapeutics Limited Ordinary Shares (2019–2024)
The table below shows the annual net assets of CytoMed Therapeutics Limited Ordinary Shares from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $6.62 Million | -22.28% |
| 2023-12-31 | $8.52 Million | +1846.51% |
| 2022-12-31 | $437.73K | -77.22% |
| 2021-12-31 | $1.92 Million | +433.44% |
| 2020-12-31 | $360.23K | -74.74% |
| 2019-12-31 | $1.43 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CytoMed Therapeutics Limited Ordinary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1006885000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $17.42 Million | 265.38% |
| Other Comprehensive Income | $14.81K | 0.23% |
| Total Equity | $6.57 Million | 100.00% |
CytoMed Therapeutics Limited Ordinary Shares Competitors by Market Cap
The table below lists competitors of CytoMed Therapeutics Limited Ordinary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Saigon Garment Manufacturing Trade JSC
VN:GMC
|
$3.83 Million |
|
Venari Minerals NL
AU:VMS
|
$3.83 Million |
|
Group 6 Metals Ltd
AU:G6M
|
$3.83 Million |
|
Kineta Inc.
NASDAQ:KA
|
$3.83 Million |
|
Cardio Diagnostics Holdings Inc
NASDAQ:CDIO
|
$3.83 Million |
|
Activeport Group Ltd
AU:ATV
|
$3.82 Million |
|
Bumi Citra Permai Tbk
JK:BCIP
|
$3.82 Million |
|
MAA Group Bhd
KLSE:1198
|
$3.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CytoMed Therapeutics Limited Ordinary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 8,521,218 to 6,565,112, a change of -1,956,106 (-23.0%).
- Net loss of 1,883,178 reduced equity.
- Other comprehensive income increased equity by 123,527.
- Other factors decreased equity by 196,455.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.88 Million | -28.68% |
| Other Comprehensive Income | $123.53K | +1.88% |
| Other Changes | $-196.46K | -2.99% |
| Total Change | $- | -22.96% |
Book Value vs Market Value Analysis
This analysis compares CytoMed Therapeutics Limited Ordinary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.83x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.05x to 1.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.26 | $1.04 | x |
| 2020-12-31 | $0.06 | $1.04 | x |
| 2021-12-31 | $0.28 | $1.04 | x |
| 2022-12-31 | $0.06 | $1.04 | x |
| 2023-12-31 | $0.80 | $1.04 | x |
| 2024-12-31 | $0.57 | $1.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CytoMed Therapeutics Limited Ordinary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3621.15%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.12x
- Recent ROE (-28.68%) is above the historical average (-185.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -44.36% | 0.00% | 0.00x | 1.52x | $-775.23K |
| 2020 | -407.14% | -3266.07% | 0.02x | 8.02x | $-1.50 Million |
| 2021 | -79.82% | -1822.31% | 0.02x | 2.35x | $-1.73 Million |
| 2022 | -518.13% | -839.94% | 0.07x | 8.90x | $-2.31 Million |
| 2023 | -36.75% | -1077.85% | 0.03x | 1.10x | $-3.98 Million |
| 2024 | -28.68% | -3621.15% | 0.01x | 1.12x | $-2.54 Million |
Industry Comparison
This section compares CytoMed Therapeutics Limited Ordinary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CytoMed Therapeutics Limited Ordinary Shares (GDTC) | $5.68 Million | -44.36% | 0.16x | $3.83 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |